Bill Marth is the correct answer. What’s amusing about all this is that I’m certain Marth never actually expected Teva to get FDA approval for generic Lovenox in 2010 and his saying he would be “deeply disappointed” by failure to get approval was nothing but propaganda.
Marth’s comment came in response to questioning by Citi analyst John Boris during Teva’s 3Q10 CC on 2-Nov-2010:
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.